<DOC>
	<DOCNO>NCT01283867</DOCNO>
	<brief_summary>To compare bioavailability characterise pharmacokinetic profile sponsor 's test formulation respect reference formulation Cellcept® 500 mg tablet , healthy , adult , human male subject non-fasting condition assess bioequivalence .</brief_summary>
	<brief_title>Bioequivalence Study Mycophenolate Mofetil 500 mg Tablets Dr.Reddy 's Laboratories Limited Under Non-Fasting Conditions</brief_title>
	<detailed_description>This open-label , balance , randomize , two-treatment , two-period , two-sequence , single dose , crossover bioequivalence study healthy , adult , human , male subject non-fasting conditions.92 healthy male adult enrolled.A washout period 07 day maintain successive dose days.One tablet contain mycophenolate mofetil 500 mg administer orally 240 mL water sit posture , 30 minute serve high fat high calorie breakfast period . This activity follow mouth check ass compliance dosing . The subject allow lie first three hour dose .</detailed_description>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>1 . Healthy male 1845 year age ( inclusive ) live around Mumbai city western part India . 2 . Having weight equal 50 Kg Body Mass Index ( BMI ) 18.524.9 ( inclusive ) , calculate weight kg / height m2 . 3 . Having significant disease clinically significant abnormal finding screen , medical history , clinical examination , laboratory evaluation , 12lead ECG chest Xray ( posteroanterior view ) recording . 4 . Able comply study procedure , opinion Principal Investigator . 5 . Able give write consent participation trial . 1 . Known hypersensitivity idiosyncratic reaction Mycophenolate Mofetil drug . 2 . Any disease condition might compromise haemopoietic , renal , hepatic , endocrine , pulmonary , central nervous , cardiovascular , immunological , dermatological , gastrointestinal body system . 3 . Ingestion medicine time 14 day dose PeriodI . In case subject selection discretion Principal Investigator /Medical Expert . 4 . Any history presence asthma ( include aspirin induce asthma ) nasal polyp NSAID induce urticaria . 5 . A recent history alcoholism ( &lt; 2 year ) moderate ( 180 mL / day ) alcohol use , consumption alcohol within 48 hour receive study medicine . 6 . Smokers , habit smoke 10 10 cigarette / day could , abstain smoking study . 7 . The presence clinically significant abnormal laboratory value screen . 8 . Use recreational drug history drug addiction test positive prestudy urine drug scan . 9 . History psychiatric disorder . 10 . A history difficulty donate blood . 11 . Donation blood ( 1 unit 350 mL ) within 90 day prior receive first dose study medicine study . Note : In case blood loss ≤ 200 mL , subject enrol 60 day blood donation . 12 . A positive hepatitis screen include hepatitis B surface antigen antiHCV antibody . 13 . A positive test result HIV antibody / syphilis . 14 . The receipt investigational product participation drug research study within period 90 day prior first dose study medication . Elimination halflife study drug take consideration inclusion subject study . Note : If subject participate study blood loss ≤ 200 mL , subject dose 60 day collection last sample previous study . 15 . An unusual diet , whatever reason ( e.g . lowsodium ) , four week prior receive study medicine throughout subject 's participation study . In case selection subject discretion Principal Investigator/Medical Expert . 16 . Uric acid parameter time screen within clinically acceptable range . 17 . History gout renal calculus . 18 . Sitting blood pressure le 100/60 mm Hg time screen . 19 . Haemoglobin le 13 gm/dL time screening .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>